NA
BMRN icon

NewEdge Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

NewEdge Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.56M Buy
27,287
+2,936
+12% +$161K ﹤0.01% 1357
2026
Q1 		$1.38M Buy
24,351
+525
+2% +$30.6K 0.01% 1314
2025
Q4 		$1.42M Sell
23,826
-505
-2% -$27.5K 0.01% 1266
2025
Q3 		$1.32M Buy
24,331
+4,667
+24% +$267K 0.01% 1241
2025
Q2 		$1.08M Buy
19,664
+15,895
+422% +$936K 0.01% 1238
2025
Q1 		$266K Buy
3,769
+388
+11% +$26.1K ﹤0.01% 1963
2024
Q4 		$222K Buy
3,381
+3,121
+1,200% +$209K ﹤0.01% 2038
2024
Q3 		$18.3K Sell
260
-10,625
-98% -$888K ﹤0.01% 2743
2024
Q2 		$896K Buy
10,885
+10,615
+3,931% +$884K 0.01% 1125
2024
Q1 		$23.6K Sell
270
-36
-12% -$3.22K ﹤0.01% 2578
2023
Q4 		$29.5K Buy
306
+134
+78% +$11.9K ﹤0.01% 2419
2023
Q3 		$15.2K Sell
172
-14
-8% -$1.25K ﹤0.01% 2450
2023
Q2 		$16.1K Sell
186
-452
-71% -$42.5K ﹤0.01% 2443
2023
Q1 		$62K Sell
638
-326
-34% -$33.8K ﹤0.01% 1909
2022
Q4 		$78.2K Buy
+964
New +$90.5K ﹤0.01% 1538
2021
Q4 		– Sell
-6,333
Closed -$489K – 1640
2021
Q3 		$489K Sell
6,333
-23
-0.4% -$1.81K 0.01% 755
2021
Q2 		$530K Buy
6,356
+139
+2% +$11K 0.01% 724
2021
Q1 		$469K Buy
6,217
+100
+2% +$8.17K 0.01% 673
2020
Q4 		$536K Buy
6,117
+2,566
+72% +$203K 0.02% 603
2020
Q3 		$270K Buy
3,551
+1,108
+45% +$112K 0.01% 747
2020
Q2 		$301K Buy
+2,443
New +$243K 0.01% 671

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

NewEdge Advisors's BMRN Position: Q2 2026 in Review

NewEdge Advisors increased its BioMarin Pharmaceuticals (BMRN) stake by 12% in Q2 2026, buying an estimated $161K and bringing the position to 27,287 shares worth $1.56M. The position accounts for ﹤0.01% of the portfolio, ranked #1357.

NewEdge Advisors first reported a position in BMRN in Q2 2020 and has held it in 21 quarters since. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • NewEdge Advisors held 27,287 shares of BioMarin Pharmaceuticals worth $1.56M as of Q2 2026.
  • NewEdge Advisors bought 2,936 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $161K.
  • BioMarin Pharmaceuticals made up ﹤0.01% of NewEdge Advisors's portfolio in Q2 2026, its #1357 holding.
  • NewEdge Advisors first reported a position in BioMarin Pharmaceuticals in Q2 2020 and has held it in 21 quarters since.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.